The FASEB Journal express article 10.1096/fj.00-0399fje. Published online December 8, 2000. Endocannabinoids control spasticity in a multiple sclerosis model

Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2‐arachidonoyl glycerol (2‐AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non‐spastic CREAE mice. While exogenously administered endocannabinoids and PEA ameliorate spasticity, selective inhibitors of endocannabinoid re‐uptake and hydrolysis—probably through the enhancement of endogenous levels of AEA, and, possibly, 2‐arachidonoyl glycerol—significantly ameliorated spasticity to an extent comparable with that observed previously with potent cannabinoid receptor agonists. These studies provide definitive evidence for the tonic control of spasticity by the endocannabinoid system and open new horizons to therapy of multiple sclerosis, and other neuromuscular diseases, based on agents modulating endocannabinoid levels and action, which exhibit little psychotropic activity.

[1]  L. Petrocellis,et al.  Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. , 2000, Chemistry and physics of lipids.

[2]  T. Bisogno,et al.  Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.

[3]  R. Pertwee.  Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development , 2000, Expert opinion on investigational drugs.

[4]  J. Brotchie,et al.  Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  A. Finazzi-Agro’,et al.  Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide* , 2000, The Journal of Biological Chemistry.

[6]  D. Smart,et al.  Anandamide: an endogenous activator of the vanilloid receptor. , 2000, Trends in pharmacological sciences.

[7]  T. Bisogno,et al.  Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9‐Tetrahydrocannabinol‐Tolerant Rats , 2000, Journal of neurochemistry.

[8]  R. Pertwee,et al.  Cannabinoids control spasticity and tremor in a multiple sclerosis model , 2000, Nature.

[9]  N. Volkow,et al.  Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). , 1999, European journal of pharmacology.

[10]  R. Pertwee,et al.  Pharmacology of cannabinoid receptor ligands. , 1999, Current medicinal chemistry.

[11]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[12]  H. Emrich,et al.  Elevated endogenous cannabinoids in schizophrenia. , 1999, Neuroreport.

[13]  L. Parsons,et al.  Dopamine activation of endogenous cannabinoid signaling in dorsal striatum , 1999, Nature Neuroscience.

[14]  T. Bisogno,et al.  Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. , 1999, Biochemical and biophysical research communications.

[15]  L. Petrocellis,et al.  Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action , 1998, Trends in Neurosciences.

[16]  P. Consroe.  Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders , 1998, Neurobiology of Disease.

[17]  M. Aceto,et al.  Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[18]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[19]  L. Petrocellis,et al.  The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. , 1998, The Biochemical journal.

[20]  R. Pertwee,et al.  Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus--longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca2+ and cAMP. , 1998, Canadian journal of physiology and pharmacology.

[21]  S. Yamamoto,et al.  Anandamide amidohydrolase reacting with 2‐arachidonoylglycerol, another cannabinoid receptor ligand , 1998, FEBS letters.

[22]  D. Piomelli,et al.  Functional role of high-affinity anandamide transport, as revealed by selective inhibition. , 1997, Science.

[23]  L. Petrocellis,et al.  Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. , 1997, The Biochemical journal.

[24]  W. A. Hill,et al.  Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. , 1997, Biochemical and biophysical research communications.

[25]  M. Palkovits,et al.  Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat , 1996, FEBS letters.

[26]  A. Fontana,et al.  The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis , 1995, Nature Medicine.

[27]  D. Gadian,et al.  Experimental encephalomyelitis modulates inositol and taurine in the spinal cord of biozzi mice , 1994, Magnetic resonance in medicine.

[28]  A. Makriyannis,et al.  (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. , 1994, Journal of medicinal chemistry.

[29]  W. Mcdonald,et al.  Intravesical capsaicin for neurogenic bladder dysfunction , 1992, The Lancet.

[30]  D. Baker,et al.  Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice , 1990, Journal of Neuroimmunology.